Malaria (Plasmodium Falciparum)NCT07903324
Permethrin-Treated Baby Wraps for Malaria Prevention in Refugee Settings
A study testing Factory-treated lesu, Soaked lesu and Untreated lesu in people with Malaria (Plasmodium Falciparum) and Malaria Incidence, run by University of North Carolina, Chapel Hill at 1 site in Uganda.
Trial summary
The objective is to test the protective effect of permethrin-treated lesus against malaria in young children in refugee settings Read more about this study
- Who is it for?
- Ages 3 months to 99 yearsHealthy volunteers can take part
- Conditions the study is for
- Malaria (Plasmodium Falciparum), Malaria Incidence
- What is being tested?
- Factory-treated lesu, Soaked lesu and Untreated lesu
- Could I receive a placebo?
- Yes, some participants may receive a placebo
- How many people
- 1,350 participants
- Where
- 1 siteUganda
- Study dates
- 1 Sep 2027to 1 Sep 2030
- Phase
- Interventional
- Are there results?
- Not yet: the study is under way
Key requirements
Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.
- Ages 3 months to 99 years
- All sexes
- Healthy volunteers accepted
- Child, Adult, Older adult
Who may be able to join
- Mother is at least 18 years old
- Dyad is considered a recent arrival ( < 18 months) to the catchment area of the settlement
- Mother is the parent or legal guardian of a singleton (i.e., not a twin) infant 3-18 months of age
- Has the ability to travel to a designated study site for visits and evaluation
Who cannot join
- Participation in another study of malaria prevention
- Known allergic reaction to permethrin
- Has a known HIV diagnosis (or exposure) or sickle cell disease
Trial locations and contacts
1 site in 1 country. Contact the study team or a site near you to ask about taking part.
Uganda1 site
Mbarara University of Science and Technology
Mbarara
Edgar Mulogo, PhD, MPH, 256-48540-20332
Edgar Mulogo, PhD, MPH
About this study
Official title: Permethrin-Treated Baby Wraps for The Prevention of Malaria in Refugee Settings
The objective is to test the protective effect of permethrin-treated lesus against malaria in young children in refugee settings
Read the detailed description
The proposed study is a randomized, double-blind trial of factory-treated, long-lasting permethrin vs. soaked permethrin vs. sham-treated (control) wraps for the prevention of malaria in young children among newly arrived refugees. Participating mother-infant pairs will receive a new bed net and two permethrin-treated or untreated lesus at enrollment. The total sample size will be 675 mother-infant pairs with 225 pairs in each group. The investigators will follow participants longitudinally for 6 months. Participants will be instructed and incentivized to present to one of the study clinics when a fever develops, where they will be evaluated, tested, and treated, if positive, for malaria. Participants will also be followed monthly for routine surveillance.
- Conditions
- Malaria (Plasmodium Falciparum), Malaria Incidence
- Being tested
- Factory-treated lesu, Soaked lesu, Untreated lesu
- Keywords
- Lesu, Malaria, Permethrin
- Medical subject headings
- Malaria, Falciparum, Malaria
What participants receive
What participants receive. In a randomised study each person is assigned to one group by chance.
Factory-treated lesuOther
Patterned cotton-blend fabric will be obtained and treated with 0.52% permethrin at Perimeter Insect Guard. After treatment, the material will be cut into 2 x 1 meter swathes
Soaked lesuOther
Wraps will be soaked in 1.0% permethrin solution donated by Sawyer Products (Safety Harbor, FL) in accordance with the manufacturer's instructions and allowed to dry. The material will be cut into 2 x 1 meter swathes
Untreated lesuOther
Untreated fabric of identical appearance (i.e., color and pattern) will be similarly cut and packaged for use
| Study group | Role | What they receive |
|---|---|---|
| Receives factory-treated permethrin lesu | Experimental | Receives factory-treated (0.52%) permethrin-treated wrap for 6 months Receives: Other: Factory-treated lesu |
| Receives soaked permethrin lesu | Experimental | Receives soaked (1%) permethrin-treated wrap for 6 months Receives: Other: Soaked lesu |
| Receives untreated lesu | Sham comparator | Receives the untreated lesu for 6 months Receives: Other: Untreated lesu |
What is being measured
The primary outcome is the main question the study is designed to answer.
Incidence of clinical malaria in children
Acute febrile illness defined as fever (temperature ≥38.0 Celsius) or fever reported in past 24 hours AND positive malaria rapid diagnostic test (RDT), confirmed by light microscopy (performed later), at scheduled or unscheduled study clinic visit
Measured: From enrollment to Month 6
Secondary outcomes (34)
Incidence of hospitalizations due to malaria
Incidence of admissions from clinic after a positive malaria RDT
Measured: From enrollment to Month 6
Incidence of hospitalizations due to any cause
Incidence of admissions from clinic after a positive malaria RDT
Measured: From enrollment to Month 6
Number of deaths due to any cause
Incidence of admissions from clinic after a positive malaria RDT
Measured: From enrollment to Month 6
Number of deaths due to malaria
Incidence of admissions from clinic after a positive malaria RDT
Measured: From enrollment to Month 6
Incidence of non-malarial febrile episodes in children
Incidence of participants experiencing acute febrile illness and negative malaria RDT at a scheduled or unscheduled study visit.
Measured: From enrollment to Month 6
Wrap attrition
The number of wraps lost or damaged and requiring replacement.
Measured: From enrollment to Month 6
Off-target use of wraps
Self-reported use for other purposes or use with other household members
Measured: From enrollment to Month 6
Incidence of malaria among mothers or other children (age < 5) in the household
Acute febrile illness defined as fever (temperature ≥38.0 Celsius) or fever reported in past 24 hours AND positive malaria rapid diagnostic test (RDT) at scheduled or unscheduled study clinic visit
Measured: From enrollment to Month 6
Perception of intervention
The median scores of the first 4 Likert-scale questions on the interview (e.g. Overall Experience). Higher scores indicate a more positive perception.
Measured: Month 6
Number of adverse reactions to wraps
Counts of the top 5 most common adverse reactions reported by participants on questionnaires and assessed by clinic staff.
Measured: From enrollment to Month 6
Number of participants with care-seeking events attributable to the wrap
Number of participants with care-seeking events attributable to the wrap.
Measured: From enrollment to Month 6
Number of participants with hospitalizations attributable to the wrap
Number of participants with hospitalizations attributable to the wrap
Measured: From enrollment to Month 6
Number of participants with death attributable to the wrap
Number of participants with death attributable to the wrap
Measured: From enrollment to Month 6
Change in child's height-for-weight
Change in Z-score for height-for-weight. A height-for-weight Z-score indicates how a child's height compares with a reference population of children of the same weight. A score of 0 represents the reference average; positive values indicate above-average height-for-weight, and negative values indicate below-average height-for-weight. Z = 0: Average height-for-weight in the reference population Z = +1: One standard deviation above the reference average Z = -1: One standard deviation below the reference average Z = -2: Substantially below the reference average
Measured: Enrollment, Month 3, Month 6
Change in child's height-for-age
Change in Z-score for height-for-age. A height-for-age Z-score indicates how a child's height compares with a reference population of children of the same age. A score of 0 represents the reference average; positive values indicate above-average height-for-age, and negative values indicate below-average height-for-age. Z = 0: Average height-for-age in the reference population Z = +1: One standard deviation above the reference average Z = -1: One standard deviation below the reference average Z = -2: Substantially below the reference average
Measured: Enrollment, Month 3, Month 6
Change in child's weight-for-age
Change in Z-score for weight-for-age. Change in Z-score for weight-for-age. A weight-for-age Z-score indicates how a child's weight compares with a reference population of children of the same age. A score of 0 represents the reference average; positive values indicate above-average weight-for-age, and negative values indicate below-average weight-for-age. Z = 0: Average weight-for-age in the reference population Z = +1: One standard deviation above the reference average Z = -1: One standard deviation below the reference average Z = -2: Substantially below the reference average
Measured: Enrollment, Month 3, Month 6
Change in child's acute malnutrition
Change in Mid-upper arm circumference (MUAC).
Measured: From enrollment to Month 6
Change in child's median score on the Mullen Scales of Early Learning
Change in median composite scores on the Mullen Scales of Early Learning. The Early Learning Composite from the Mullen Scales of Early Learning (MSEL) will be used to measure developmental functioning. The Early Learning Composite (ELC) is a standardized composite score derived from the 5 subtests measured on the MSEL. It has a mean of 100 and a standard deviation of 15. Higher scores indicate stronger performance.
Measured: From enrollment to Month 6
Change in child's mean score on the Mullen Scales of Early Learning
Change in mean composite scores on the Mullen Scales of Early Learning. The Early Learning Composite from the Mullen Scales of Early Learning (MSEL) will be used to measure developmental functioning. The Early Learning Composite (ELC) is a standardized composite score derived from the 5 subtests measured on the MSEL. It has a mean of 100 and a standard deviation of 15. Higher scores indicate stronger performance.
Measured: From enrollment to Month 6
Change in child's percentile on the Developmental Profile 4: Physical Scale
Performance on the Physical subscale of the Developmental Profile 4, which includes items measuring gross- and fine-motor skills, coordination, strength, stamina, and flexibility. Expressed as a percentile from 0 to 100%, where a score of 50% indicates that the child performs equal to their same age peers, a score above 50% indicates they perform better than their same age peers, and a score below 50% indicates they perform worse than their same age peers.
Measured: From enrollment to Month 6
Change in child's percentile on the Developmental Profile 4: Adaptive Behavior Scale
Performance on the Adaptive Behavior subscale of the Developmental Profile 4, which includes items measuring age-appropriate independent functioning. Expressed as a percentile from 0 to 100%, where a score of 50% indicates that the child performs equal to their same age peers, a score above 50% indicates they perform better than their same age peers, and a score below 50% indicates they perform worse than their same age peers.
Measured: From enrollment to Month 6
Change in child's percentile on the Developmental Profile 4: Social-Emotional Scale
Performance on the Social-Emotional subscale of the Developmental Profile 4, which includes items measuring skills related to interpersonal behavior and demonstration of social and emotional competence. Expressed as a percentile from 0 to 100%, where a score of 50% indicates that the child performs equal to their same age peers, a score above 50% indicates they perform better than their same age peers, and a score below 50% indicates they perform worse than their same age peers.
Measured: From enrollment to Month 6
Change in child's percentile on the Developmental Profile 4: Cognitive Scale
Performance on the Cognitive subscale of the Developmental Profile 4, which includes items measuring perception, concept development, number relations, reasoning, memory, classification, time concepts, and related mental acuity tasks. Expressed as a percentile from 0 to 100%, where a score of 50% indicates that the child performs equal to their same age peers, a score above 50% indicates they perform better than their same age peers, and a score below 50% indicates they perform worse than their same age peers
Measured: From enrollment to Month 6
Change in child's percentile on the Developmental Profile 4: Communication Scale
Performance on the Communication subscale of the Developmental Profile 4, which reflects the ability to understand spoken and written language as well as to use both verbal and nonverbal skills to communicate. Expressed as a percentile from 0 to 100%, where a score of 50% indicates that the child performs equal to their same age peers, a score above 50% indicates they perform better than their same age peers, and a score below 50% indicates they perform worse than their same age peers.
Measured: From enrollment to Month 6
Change in child's growth score on the Developmental Profile 4: Physical Scale
Performance on the Physical subscale of the Developmental Profile 4, which is expressed as a a raw score from 40 to 160 that is designed specifically to track progress and monitor developmental change over time, where higher scores indicate better performance
Measured: From enrollment to Month 6
Change in child's growth score on the Developmental Profile 4: Adaptive Behavior Scale
Performance on the Adaptive Behavior subscale of the Developmental Profile 4, which is expressed as a a raw score from 40 to 160 that is designed specifically to track progress and monitor developmental change over time, where higher scores indicate better performance
Measured: From enrollment to Month 6
Change in child's growth score on the Developmental Profile 4: Social-Emotional Scale
Performance on the Social-Emotional subscale of the Developmental Profile 4, which is expressed as a a raw score from 40 to 160 that is designed specifically to track progress and monitor developmental change over time, where higher scores indicate better performance
Measured: From enrollment to Month 6
Change in child's growth score on the Developmental Profile 4: Cognitive Scale
Performance on the Cognitive subscale of the Developmental Profile 4, which is expressed as a a raw score from 40 to 160 that is designed specifically to track progress and monitor developmental change over time, where higher scores indicate better performance
Measured: From enrollment to Month 6
Change in child's growth score on the Developmental Profile 4: Communication Scale
Performance on the Communication subscale of the Developmental Profile 4, which is expressed as a a raw score from 40 to 160 that is designed specifically to track progress and monitor developmental change over time, where higher scores indicate better performance
Measured: From enrollment to Month 6
Change in child's age equivalent on the Developmental Profile 4: Physical Scale
Performance on the Physical subscale of the Developmental Profile 4, which translates the child's performance to the age at which an average child achieves those same raw scores. Expressed as a metric in the format X:Y where X equals the number of years old, and Y equals a number between 0 and 11. Values higher than the child's age-equivalence reflects developmental functioning consistent with that of older children
Measured: From enrollment to Month 6
Change in child's age equivalent on the Developmental Profile 4: Adaptive Behavior Scale
Performance on the Adaptive Behavior subscale of the Developmental Profile 4, which translates the child's performance to the age at which an average child achieves those same raw scores. Expressed as a metric in the format X:Y where X equals the number of years old, and Y equals a number between 0 and 11. Values higher than the child's age-equivalence reflects developmental functioning consistent with that of older children
Measured: From enrollment to Month 6
Change in child's age equivalent on the Developmental Profile 4: Social-Emotional Scale
Performance on the Social-Emotional subscale of the Developmental Profile 4, which translates the child's performance to the age at which an average child achieves those same raw scores. Expressed as a metric in the format X:Y where X equals the number of years old, and Y equals a number between 0 and 11. Values higher than the child's age-equivalence reflects developmental functioning consistent with that of older children.
Measured: From enrollment to Month 6
Change in child's age equivalent on the Developmental Profile 4: Cognitive Scale
Performance on the Cognitive subscale of the Developmental Profile 4, which translates the child's performance to the age at which an average child achieves those same raw scores. Expressed as a metric in the format X:Y where X equals the number of years old, and Y equals a number between 0 and 11. Values higher than the child's age-equivalence reflects developmental functioning consistent with that of older children
Measured: From enrollment to Month 6
Change in child's age equivalent on the Developmental Profile 4: Communication Scale
Performance on the Communication subscale of the Developmental Profile 4, which translates the child's performance to the age at which an average child achieves those same raw scores. Expressed as a metric in the format X:Y where X equals the number of years old, and Y equals a number between 0 and 11. Values higher than the child's age-equivalence reflects developmental functioning consistent with that of older children.
Measured: From enrollment to Month 6
Timeline
From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.
- First posted29 Oct 2026
- Study start1 Sep 2027 (estimated)
- Primary completion1 Sep 2029 (estimated)
- Study completion1 Sep 2030 (estimated)
Resources
- Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
- Other trials for Malaria (Plasmodium Falciparum)Studies of the same condition, open and under way.
- More trials run by University of North Carolina, Chapel HillThe sponsor's other registered studies.
- What the trial phases meanHow a treatment moves from first tests in people to approval.
More details
For doctors and researchers: how the study is designed, who runs it, and its registry IDs.
Study design
- Study type
- Interventional
- Phase
- Phase N/A
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind
- Who is masked
- Participant, Care provider
- Enrolment
- 1,350 participants (estimated)
Sponsor and investigators
- Lead sponsor
- University of North Carolina, Chapel Hill
- Sponsor type
- University, hospital or other
- Collaborators
- Mbarara University of Science and Technology
- Responsible party
- Sponsor
- Investigators
- Ross Boyce, MD, MSc, Principal investigator, University of North Carolina, Chapel Hill
IDs, dates and publications
- ClinicalTrials.gov ID
- NCT07903324
- Sponsor's protocol ID
- 26-2587
- Status last verified
- Oct 2026
- First submitted
- 21 Oct 2026
- Last updated
- 29 Oct 2026
- Results posted
- No
- Data monitoring committee
- Yes
- FDA-regulated drug
- No
- FDA-regulated device
- No
- Individual data sharing
- Yes: Deidentified individual data that supports the results may be shared beginning 9 and continuing for 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.
Study at a glance
From the registry record, last updated by the sponsor on 29 Oct 2026. Recruitment status is as the sponsor reported it: confirm with the study team.
- Official title
- Permethrin-Treated Baby Wraps for The Prevention of Malaria in Refugee Settings
- ClinicalTrials.gov ID
- NCT07903324
- Acronym / sponsor ID
- 26-2587
- Conditions
- Malaria (Plasmodium Falciparum), Malaria Incidence
- Keywords
- Lesu, Malaria, Permethrin
- Study type
- Interventional
- Recruitment status
- Not yet recruiting
- Enrolment
- 1,350 participants (estimated)
- Lead sponsor
- University of North Carolina, Chapel HillUniversity, hospital or other
- Collaborators
- Mbarara University of Science and Technology
- Study start
- 1 Sep 2027 (estimated)
- Primary completion
- 1 Sep 2029 (estimated)
- Study completion
- 1 Sep 2030 (estimated)
- First posted
- 29 Oct 2026 (actual)
- Results
- Not posted in the source record
Clinical summary
The research question as the sponsor registered it. This describes what the study plans to test, not what it found.
The objective is to test the protective effect of permethrin-treated lesus against malaria in young children in refugee settings
Detailed description
The proposed study is a randomized, double-blind trial of factory-treated, long-lasting permethrin vs. soaked permethrin vs. sham-treated (control) wraps for the prevention of malaria in young children among newly arrived refugees. Participating mother-infant pairs will receive a new bed net and two permethrin-treated or untreated lesus at enrollment. The total sample size will be 675 mother-infant pairs with 225 pairs in each group. The investigators will follow participants longitudinally for 6 months. Participants will be instructed and incentivized to present to one of the study clinics when a fever develops, where they will be evaluated, tested, and treated, if positive, for malaria. Participants will also be followed monthly for routine surveillance.
Study design
- Primary purpose
- Prevention
- Allocation
- Randomised
- Intervention model
- Parallel groups
- Masking
- Double blind (participant, care provider)
- Number of arms
- 3
| Arm | Type | Receives |
|---|---|---|
| Receives factory-treated permethrin lesu | Experimental | Other: Factory-treated lesuReceives factory-treated (0.52%) permethrin-treated wrap for 6 months |
| Receives soaked permethrin lesu | Experimental | Other: Soaked lesuReceives soaked (1%) permethrin-treated wrap for 6 months |
| Receives untreated lesu | Sham comparator | Other: Untreated lesuReceives the untreated lesu for 6 months |
Who may qualify
- Ages
- 3 months to 99 years
- Sex
- All
- Healthy volunteers
- Accepted
- Age groups
- Child, Adult, Older adult
Key inclusion criteria (4 listed)
- Mother is at least 18 years old
- Dyad is considered a recent arrival ( < 18 months) to the catchment area of the settlement
- Mother is the parent or legal guardian of a singleton (i.e., not a twin) infant 3-18 months of age
- Has the ability to travel to a designated study site for visits and evaluation
Key exclusion criteria (3 listed)
- Participation in another study of malaria prevention
- Known allergic reaction to permethrin
- Has a known HIV diagnosis (or exposure) or sickle cell disease
Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.
Interventions
| Intervention | Type | Arms |
|---|---|---|
| Factory-treated lesuPatterned cotton-blend fabric will be obtained and treated with 0.52% permethrin at Perimeter Insect Guard. After treatment, the material will be cut into 2 x 1 meter swathes | Other | Receives factory-treated permethrin lesu |
| Soaked lesuWraps will be soaked in 1.0% permethrin solution donated by Sawyer Products (Safety Harbor, FL) in accordance with the manufacturer's instructions and allowed to dry. The material will be cut into 2 x 1 meter swathes | Other | Receives soaked permethrin lesu |
| Untreated lesuUntreated fabric of identical appearance (i.e., color and pattern) will be similarly cut and packaged for use | Other | Receives untreated lesu |
Primary outcome
Incidence of clinical malaria in children
Time frame: From enrollment to Month 6
Acute febrile illness defined as fever (temperature ≥38.0 Celsius) or fever reported in past 24 hours AND positive malaria rapid diagnostic test (RDT), confirmed by light microscopy (performed later), at scheduled or unscheduled study clinic visit
34 secondary outcomes
Incidence of hospitalizations due to malaria
Time frame: From enrollment to Month 6
Incidence of hospitalizations due to any cause
Time frame: From enrollment to Month 6
Number of deaths due to any cause
Time frame: From enrollment to Month 6
Number of deaths due to malaria
Time frame: From enrollment to Month 6
Incidence of non-malarial febrile episodes in children
Time frame: From enrollment to Month 6
Wrap attrition
Time frame: From enrollment to Month 6
Off-target use of wraps
Time frame: From enrollment to Month 6
Incidence of malaria among mothers or other children (age < 5) in the household
Time frame: From enrollment to Month 6
Perception of intervention
Time frame: Month 6
Number of adverse reactions to wraps
Time frame: From enrollment to Month 6
Number of participants with care-seeking events attributable to the wrap
Time frame: From enrollment to Month 6
Number of participants with hospitalizations attributable to the wrap
Time frame: From enrollment to Month 6
Number of participants with death attributable to the wrap
Time frame: From enrollment to Month 6
Change in child's height-for-weight
Time frame: Enrollment, Month 3, Month 6
Change in child's height-for-age
Time frame: Enrollment, Month 3, Month 6
Change in child's weight-for-age
Time frame: Enrollment, Month 3, Month 6
Change in child's acute malnutrition
Time frame: From enrollment to Month 6
Change in child's median score on the Mullen Scales of Early Learning
Time frame: From enrollment to Month 6
Change in child's mean score on the Mullen Scales of Early Learning
Time frame: From enrollment to Month 6
Change in child's percentile on the Developmental Profile 4: Physical Scale
Time frame: From enrollment to Month 6
Change in child's percentile on the Developmental Profile 4: Adaptive Behavior Scale
Time frame: From enrollment to Month 6
Change in child's percentile on the Developmental Profile 4: Social-Emotional Scale
Time frame: From enrollment to Month 6
Change in child's percentile on the Developmental Profile 4: Cognitive Scale
Time frame: From enrollment to Month 6
Change in child's percentile on the Developmental Profile 4: Communication Scale
Time frame: From enrollment to Month 6
Change in child's growth score on the Developmental Profile 4: Physical Scale
Time frame: From enrollment to Month 6
Change in child's growth score on the Developmental Profile 4: Adaptive Behavior Scale
Time frame: From enrollment to Month 6
Change in child's growth score on the Developmental Profile 4: Social-Emotional Scale
Time frame: From enrollment to Month 6
Change in child's growth score on the Developmental Profile 4: Cognitive Scale
Time frame: From enrollment to Month 6
Change in child's growth score on the Developmental Profile 4: Communication Scale
Time frame: From enrollment to Month 6
Change in child's age equivalent on the Developmental Profile 4: Physical Scale
Time frame: From enrollment to Month 6
Change in child's age equivalent on the Developmental Profile 4: Adaptive Behavior Scale
Time frame: From enrollment to Month 6
Change in child's age equivalent on the Developmental Profile 4: Social-Emotional Scale
Time frame: From enrollment to Month 6
Change in child's age equivalent on the Developmental Profile 4: Cognitive Scale
Time frame: From enrollment to Month 6
Change in child's age equivalent on the Developmental Profile 4: Communication Scale
Time frame: From enrollment to Month 6
Results and safety
This study is still under way. Results are not available in the source record yet.
Research links
- Official record on ClinicalTrials.govLast updated by the sponsor 29 Oct 2026.
- Individual participant dataSharing planned: Yes. Deidentified individual data that supports the results may be shared beginning 9 and continuing for 36 months following publication provided the investigator who proposes to use the data has approval from an Institutional Review Board (IRB), Independent Ethics Committee (IEC), or Research Ethics Board (REB), as applicable, and executes a data use/sharing agreement with UNC.
Related trials for Malaria (Plasmodium Falciparum)
RecruitingPhase 1
Safety, Tolerability and Efficacy of PfSPZ-LARC2 Vaccine Against CHMI in Malaria-Naïve Adults
Malaria Falciparum
Not yet recruiting
Three-arm Cluster Randomised Control Trial Evaluation of Guardian Spatial Emanator as a Complimentary Vector Control Tool in Papua New Guinea
Malaria
Active, not recruitingPhase 4
Improving Neonatal Health Through Rapid Malaria Testing in Early Pregnancy With High-Sensitivity Diagnostics
Malaria,Falciparum, Malaria in Pregnancy
RecruitingPhase 1/2
DON in Pediatric Cerebral Malaria
Malaria, Cerebral
Not yet recruitingPhase 1
Safety and Immunogenicity of the Recombinant Malaria Vaccines in Healthy Adults Aged 18-50 Years
Malaria Vaccine
Referral and contact
AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part.
Ross Boyce, MD, MSc principal investigator
University of North Carolina, Chapel Hill
1 site in 1 country: see every site and its status.
Questions about this trial
What is this clinical trial studying?
A study testing Factory-treated lesu, Soaked lesu and Untreated lesu in people with Malaria (Plasmodium Falciparum) and Malaria Incidence, run by University of North Carolina, Chapel Hill at 1 site in Uganda.
The full registered description is in the About this study section and the official record.
Who may be eligible to take part?
The sponsor lists 4 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.
Is this clinical trial currently recruiting?
The record says: opening soon, as of the sponsor's last update on 29 Oct 2026. Status can change between updates, so confirm with the study contact before making plans.
Where is the study taking place?
The record lists 1 site in Uganda. Whether a site is taking part right now should be confirmed with that site. See every site.
What are the possible benefits and risks?
They depend on the study and the treatment, and no study can promise a benefit. Some participants in this study may receive a placebo. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.
Are results available for this study?
This study is still under way. Results are not available in the source record yet.
How can a doctor refer a patient or contact the research team?
Contact Ross Boyce, MD, MSc (919-966-2537, ross_boyce@med.unc.edu), or a site near the patient. AzTrials does not enrol participants or take referrals.
What does the primary outcome measure?
Incidence of clinical malaria in children (time frame: From enrollment to Month 6). It is what the study was designed to measure, not a finding.
Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?
No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.
How often is this information updated?
AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Oct 2026.